Trial · NCT04739306
Adverse events186
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 186
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Cataract | Eye disorders | CT-P42 (Main Study Period) | 6 | 174 | 6 |
| other | Cataract | Eye disorders | Eylea (Main Study Period) | 4 | 174 | 4 |
| other | Cataract | Eye disorders | CT-P42 (Extension Study Period) | 0 | 31 | 0 |
| other | Conjunctival haemorrhage | Eye disorders | CT-P42 (Main Study Period) | 2 | 174 | 2 |
| other | Conjunctival haemorrhage | Eye disorders | Eylea (Main Study Period) | 4 | 174 | 5 |
| other | Conjunctival haemorrhage | Eye disorders | CT-P42 (Extension Study Period) | 0 | 31 | 0 |
| other | Conjunctival haemorrhage | Eye disorders | CT-P42 (Main Study Period) | 2 | 174 | 2 |
| other | Conjunctival haemorrhage | Eye disorders | Eylea (Main Study Period) | 4 | 174 | 5 |
| other | Conjunctival haemorrhage | Eye disorders | CT-P42 (Extension Study Period) | 0 | 31 | 0 |
| other | Diabetic retinal oedema | Eye disorders | CT-P42 (Main Study Period) | 17 | 174 | 18 |
| other | Diabetic retinal oedema | Eye disorders | Eylea (Main Study Period) | 23 | 174 | 26 |
| other | Diabetic retinal oedema | Eye disorders | CT-P42 (Extension Study Period) | 1 | 31 | 1 |
| other | Posterior capsule opacification | Eye disorders | CT-P42 (Main Study Period) | 4 | 174 | 5 |
| other | Posterior capsule opacification | Eye disorders | Eylea (Main Study Period) | 3 | 174 | 3 |
| other | Posterior capsule opacification | Eye disorders | CT-P42 (Extension Study Period) | 0 | 31 | 0 |
| other | Visual acuity reduced | Eye disorders | CT-P42 (Main Study Period) | 5 | 174 | 5 |
| other | Visual acuity reduced | Eye disorders | Eylea (Main Study Period) | 4 | 174 | 4 |
| other | Visual acuity reduced | Eye disorders | CT-P42 (Extension Study Period) | 0 | 31 | 0 |
| other | Vitreous floaters | Eye disorders | CT-P42 (Main Study Period) | 3 | 174 | 3 |
| other | Vitreous floaters | Eye disorders | Eylea (Main Study Period) | 4 | 174 | 4 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04739306/events